The investment bank said the recent pullback in the company's stock has made its valuation more attractive.
Research centers in six countries will work on metabolome-related global health challenges including autism, cancer, diabetes, dementia, and obesity.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
Posting strong pharma sales but weakness in academia and government, Waters matched analysts' average EPS estimate for the quarter but fell short on revenues.
Among the launches at the organization's annual meeting this week in Taipei were a personalized proteomics initiative and a new DIA mass spec method.
The company posted Q2 revenues of $536.6 million, up from $494.7 million in Q2 2015 and beating the average Wall Street estimate of $523.4 million.
The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.
While most firms launched new mass spec systems, the larger focus was on developing and implementing the larger workflows surrounding these instruments.
Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.
The firm sold three series of senior notes and will use proceeds to repay other outstanding debt.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.